Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Citius Oncology, Inc.NASDAQ: CTOR
Other Current Assets · Q2 FY2026 · quarter ended Mar 2026
Other current assets remains negative
Q2 FY2026 other current assets was $0, compared with $0 a year earlier.
Context
- Other current assets amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Other current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 0 | — |
| FY2024 | 2024-09-30 | 0 | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Other Current Assets vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 other current assets of $0 is the lowest of the 10 companies compared; the peer median is $1.77M.
- Other current assets amounts to 0.0% of total assets for CTOR, versus a peer median of 1.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.23M | -54.4% | — | 1.4% | |
| Mar 2026 | $4M | -25.7% | -46.8% | 1.4% | |
| Mar 2026 | $3.39M | -10.0% | — | 3.9% | |
| Mar 2026 | $2.86M | +862.6% | -9.3% | 0.6% | |
| Mar 2026 | $1.77M | -37.8% | -37.7% | 1.5% | |
| Mar 2026 | $1.44M | -7.0% | -21.5% | 2.4% | |
| Mar 2026 | $625K | -54.5% | -5.5% | 0.9% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $385.44K | +7.3% | +143.0% | 4.3% |
| Mar 2026 | $242K | -46.1% | +82.0% | 0.4% | |
CTORCitius Oncology, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding CTOR) | $1.77M | -25.7% | -9.3% | 1.4% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.